Coya Therapeutics, Inc. , a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells , today announced its financial.
Coya Therapeutics, Inc Provides Business Update and Reports Q3 2023 Unaudited Financial Results pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Using proprietary exosome tethering modification technology, Treg derived exosomes were engineered with a surface protein, cytotoxic T lymphocyte associated protein 4 to increase selective.
Dr. Phil Campbell, Professor at Carnegie Mellon University , will present proof of concept data, on behalf of Coya, illustrating the ability to modify Regulatory T cell exosomes to enable selective.